Supplementary Figure S2 from Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy

Key Points

• Hematologic toxicity is influenced by clonal hematopoiesis and baseline ferritin levels in patients undergoing CAR-T therapy.
• Patients with higher baseline ferritin experienced different myeloid recovery times, indicating a significant predictor role of clonal hematopoiesis.
• Survival analysis showed medians and hazard ratios that highlight the impact of clonal mutations on recovery times.
• The study involved 90 patients with evaluable next-generation sequencing data to assess the link between mutations and outcomes.